Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Nebulized Ensifentrine

Phase 2Small molecule

VVerona Pharma plc

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Cystic Fibrosis BronchiectasisRecruiting

Non-Cystic Fibrosis BronchiectasisPhase 2

Recruiting

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Non-Cystic Fibrosis Bronchiectasis

NCT06559150

Clinical

Trials by Indication[1]

Non-cystic Fibrosis Bronchiectasis1 trial

A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis

Recruiting·VVerona Pharma plc·Phase 2·NCT06559150·284 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nebulized Ensifentrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nebulized Ensifentrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nebulized Ensifentrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Verona Pharma plc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVerona Pharma plc

Related News